AEON Biopharma, Inc.
AEON Biopharma, Inc.
Insider Sentiment (TTM):
Last Purchase:2025-05-21Last Sale:2023-08-11Shares Purchased (TTM):0Shares Sold (TTM):0
Institutional Sentiment:
As of:2026-03-31Institutional Shares Owned:2,841,419Shares Outstanding:40,614,087Institutional Ownership Pct.:7.00%
Earnings Market Reaction:
Filing Date:2026-05-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Common Class B | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Cash And Cash Equivalents At Carrying Value | 6 | 3 | 6 | 8 | 10 | 0 | 1 | 3 | 2 | 5 | 16 | 0 | |||||
Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Prepaid Expense And Other Assets Current | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | - | |||||
Assets Current | 7 | 3 | 7 | 10 | 12 | 2 | 2 | 4 | 2 | 6 | 17 | 1 | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | - | |||||
Other Assets Noncurrent | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Assets | 9 | 6 | 9 | 12 | 14 | 3 | 4 | 6 | 3 | 7 | 18 | 22 | |||||
Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 7 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Assets Held In Trust Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 21 | |||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 1 | 1 | 3 | 4 | 2 | 6 | 5 | 3 | 7 | 3 | 4 | - | |||||
Employee Related Liabilities Current | 2 | 3 | 2 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 1 | - | |||||
Sales And Excise Tax Payable Current | - | - | - | - | - | - | - | - | - | - | 1 | 0 | |||||
Accrued Income Taxes Current | - | - | - | - | - | - | - | - | - | - | - | 1 | |||||
Other Accrued Liabilities Current | 2 | 2 | 3 | 3 | 3 | 4 | 3 | 4 | 4 | 4 | 3 | - | |||||
Liabilities Current | 7 | 7 | 8 | 9 | 9 | 14 | 11 | 10 | 16 | 13 | 14 | 9 | |||||
Convertible Long Term Notes Payable | 2 | 35 | 17 | 15 | 13 | 12 | 15 | 13 | 5 | - | - | - | |||||
Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | 0 | - | |||||
Derivative Liabilities Noncurrent | - | 15 | - | - | - | - | - | - | - | - | - | - | |||||
Warrants And Rights Outstanding | 16 | 3 | 2 | 2 | 2 | 1 | 2 | 1 | 12 | 1 | 2 | 1 | |||||
Notes Payable Related Parties Classified Current | - | - | - | - | - | - | - | - | - | - | 0 | - | |||||
Notes Payable Related Parties Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | - | |||||
Liabilities | 25 | 61 | 29 | 28 | 25 | 32 | 36 | 34 | 201 | 160 | 146 | 12 | |||||
Temporary Equity Carrying Amount Attributable To P… | - | - | - | - | - | - | - | - | - | - | - | 21 | |||||
Stockholders Equity Inclu… | |||||||||||||||||
Stockholders Equity | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Additional Paid In Capital | 466 | 416 | 414 | 413 | 411 | 403 | 402 | 400 | 393 | 381 | 380 | 0 | |||||
Retained Earnings Accumulated Deficit | -483 | -471 | -434 | -429 | -423 | -432 | -434 | -428 | -592 | -474 | -447 | -11 | |||||
Stockholders Equity | -17 | -55 | -20 | -16 | -11 | -29 | -32 | -28 | -198 | -153 | -128 | -11 | |||||
Liabilities And Stockholders Equity | 9 | 6 | 9 | 12 | 14 | 3 | 4 | 6 | 3 | 7 | 18 | 22 | |||||
Common Class A | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Common Classa Subject To Redemption | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Common Classa Not Subject To Redemption | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 1 | |||||
Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Notes Payable Current | - | - | - | - | - | - | - | - | - | 0 | 0 | - | |||||
Long Term Notes Payable | - | - | - | - | - | - | - | - | - | - | 0 | - | |||||
Related Party | 2 | 35 | 2 | 2 | 13 | 12 | 2 | 13 | - | 0 | - | - | |||||
Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | 0 | 0 | - | |||||
Treasury Stock Shares | - | - | - | - | - | - | - | - | - | - | 0 | - | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Common Stock Shares Authorized | 1,040 | 1,040 | 1,040 | 1,040 | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 | - | |||||
Common Stock Shares Issued | 25 | 24 | 23 | 23 | 21 | 1 | 40 | 39 | 38 | 37 | 37 | - | |||||
Shares Outstanding | 51 | 48 | 47 | 46 | 42 | 47 | 1,108 | 1,095 | 1,067 | 1,040 | 1,040 | - | |||||
Treasury Stock Common Shares | - | - | - | - | - | - | - | - | - | 0 | 0 | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
0/5
Search a metric to start building a table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
0/1
Search a metric to start building a visual
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.86% | -10.74% | - | - | - | - | - | - | - | - | - | - |
| 2025 | 64.66% | 68.27% | 36.55% | 10.74% | 17.56% | 23.37% | -25.75% | 22.65% | 28.18% | 6.06% | -21.52% | -32.53% |
| 2024 | 3.07% | -40.00% | -35.58% | -23.10% | 21.00% | -12.00% | -6.38% | -17.54% | -81.30% | -44.06% | -30.94% | 25.83% |
| 2023 | -2.22% | -27.05% | -23.00% | -35.24% | -56.00% | -38.56% | 46.25% | 70.46% | 74.33% | - | - | - |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 0.99 | 0.49 | 0.90 | 1.12 | 1.43 | 0.11 | 0.22 | 0.39 | 0.16 | 0.48 | 1.19 | 0.06 | |||||
| Quick Ratio | 0.94 | 0.44 | 0.72 | 0.92 | 1.21 | 0.00 | 0.05 | 0.33 | 0.10 | 0.40 | 1.14 | 0.05 | |||||
| Working Capital | -44.00K | -3.50M | -816.00K | 1.13M | 3.68M | -12.56M | -8.36M | -6.41M | -13.46M | -6.83M | 2.73M | -8.87M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | -1.52 | -1.10 | -1.44 | -1.74 | -2.22 | -1.11 | -1.12 | -1.21 | -1.02 | -1.04 | -1.14 | -1.05 | |||||
| Debt Ratio | 2.94 | 10.90 | 3.28 | 2.36 | 1.82 | 10.09 | 9.01 | 5.87 | 66.43 | 23.36 | 8.29 | 0.55 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -1.48 | -0.99 | -0.00 | -0.04 | 3.54 | 0.87 | 0.39 | 1.64 | -2.15 | 0.55 | 1.06 | -0.06 | |||||
| Free Cash Flow Per Share TTM | -0.30 | -0.44 | -0.28 | -0.31 | -0.41 | -0.45 | -0.21 | -0.48 | -0.54 | -0.60 | -0.24 | -0.55 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | -135.54% | -193.37% | -100.02% | -102.20% | -280.71% | 74.69% | -60.89% | -2,968.67% | -3,012.26% | 277.17% | 605.13% | -124.61% | |||||
| EPS Growth (1Y) | -141.85% | -206.79% | -100.02% | -102.25% | -264.41% | 66.85% | -63.24% | -2,661.49% | -2,810.49% | 250.18% | 558.68% | -124.47% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -0.67 | -1.11 | -12,550.23 | -20.61 | 0.16 | 42.01 | 193.63 | 46.03 | -388.27 | 934.63 | 379.58 | -7,950.89 | |||||
| P/B TTM | -2.39 | -0.79 | -1.89 | -2.13 | -2.45 | -61.77 | -108.68 | -122.67 | -183.16 | -146.85 | -136.14 | -1,800.91 | |||||
| Market Cap | 40.00M | 43.65M | 37.65M | 33.72M | 27.73M | 1.76B | 3.49B | 3.43B | 36.34B | 22.47B | 17.48B | 20.64B | |||||
| Enterprise Value | 35.30M | 75.25M | 48.77M | 40.45M | 30.61M | 1.78B | 3.50B | 3.44B | 36.34B | 22.47B | 17.46B | 20.64B | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -12.04M | -17.32M | -13.23M | -13.58M | -19.61M | -20.29M | -9.55M | -21.65M | -23.62M | -26.08M | -10.52M | -22.16M | |||||
| Net Debt | -4.70M | 31.59M | 11.12M | 6.74M | 2.87M | 11.68M | 14.63M | 9.85M | 3.53M | -5.16M | -16.18M | -2.60M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
2025-05-21Purchase
Owner: Fischer, Jost
Title: -
Shares: 60,000
Price/Share: $0.49
Value: $29,400.00
Shares Owned: 266,785
Relationship: Director
Ownership: Direct
2025-05-20Purchase
Owner: Fischer, Jost
Title: -
Shares: 60,000
Price/Share: $0.51
Value: $30,600.00
Shares Owned: 206,785
Relationship: Director
Ownership: Direct
2023-08-11Sale
Owner: Strathspey, Crown Holding…
Title: -
Shares: 7,380,394
Price/Share: $10.00
Value: $73,803,940.00
Shares Owned: 2,031,773
Relationship: TenPercentOwner
Ownership: Direct
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
No data available for chart
2026-03-31
7.00%
Inst. Shares: 2,841,419
Shares Outstanding: 40,614,087
2025-12-31
6.16%
Inst. Shares: 2,443,029
Shares Outstanding: 39,686,348
2025-09-30
5.86%
Inst. Shares: 2,728,894
Shares Outstanding: 46,539,784
2025-06-30
5.53%
Inst. Shares: 2,452,006
Shares Outstanding: 44,363,236
2025-03-31
6.39%
Inst. Shares: 3,053,552
Shares Outstanding: 47,818,512
AEON Biopharma, Inc. (AEON) — SEC Financial Statements & Analysis
AEON Biopharma, Inc. (AEON) is a pharmaceutical preparations company, incorporated in DE. AEON Biopharma, Inc. trades on NYSE as: AEON. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), AEON Biopharma, Inc. reported a Debt-to-Equity ratio of -1.52x, a Price-to-Book (P/B) ratio of -2.39 (TTM), at a market cap of $40.00M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -1.52x
- P/B TTM
- -2.39
- Market Cap
- $40.00M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AEON Biopharma, Inc. in?
AEON Biopharma, Inc. (AEON) operates in the Pharmaceutical Preparations industry.
What is AEON's market cap?
AEON Biopharma, Inc. (AEON) has a market capitalization of $40.00M as of 2026-03-31.
What exchange does AEON trade on?
AEON Biopharma, Inc. (AEON) trades on the NYSE.
Where is AEON Biopharma, Inc. incorporated?
AEON Biopharma, Inc. is incorporated in DE.